Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

NCT02983097 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

OTHER

Sponsor class

Stopped Phase II: no scientific interests are given anymore

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma Grade III (FL III°)
Mantle Cell Lymphoma (MCL), Blastoid Variant
Burkitt Lymphoma (BL)
Aggressive Marginal Zone Lymphoma (MZL)

Interventions

DRUG: Rituximab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Dexamethasone
DRUG: Cytarabine
DRUG: Lenalidomide
DRUG: PegFilgrastim
PROCEDURE: peripheral stem cell collection

Sponsor

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Collaborators

[object Object]
[object Object]